Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
105.3 USD | -0.17% | -0.74% | -14.41% |
Financials (USD)
Sales 2024 * | 4.05B | Sales 2025 * | 4.36B | Capitalization | 6.63B |
---|---|---|---|---|---|
Net income 2024 * | 430M | Net income 2025 * | 597M | EV / Sales 2024 * | 2.5 x |
Net Debt 2024 * | 3.48B | Net Debt 2025 * | 2.23B | EV / Sales 2025 * | 2.03 x |
P/E ratio 2024 * |
17.9
x | P/E ratio 2025 * |
12.3
x | Employees | 2,800 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.22% |
Latest transcript on Jazz Pharmaceuticals plc
1 day | -0.17% | ||
1 week | -0.74% | ||
Current month | +0.03% | ||
1 month | -4.94% | ||
3 months | -11.46% | ||
6 months | -10.95% | ||
Current year | -14.41% |
Managers | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Renée Galá
PSD | President | 52 | 20-03-15 |
Robert Iannone
CTO | Chief Tech/Sci/R&D Officer | 57 | 19-05-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bruce Cozadd
CEO | Chief Executive Officer | 60 | 03-02-28 |
Norbert Riedel
BRD | Director/Board Member | 66 | 13-05-12 |
Patrick Enright
BRD | Director/Board Member | 62 | 08-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
19.34% | 13 M€ | -.--% | ||
14.47% | 254 M€ | +13.69% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 105.2 | -0.20% | 4,967,465 |
24-05-30 | 105.5 | +1.16% | 582,273 |
24-05-29 | 104.2 | -0.77% | 765,239 |
24-05-28 | 105.1 | -0.94% | 627,937 |
24-05-24 | 106.1 | +2.04% | 675,815 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.41% | 6.64B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- JAZZ Stock